<DOC>
	<DOCNO>NCT02900651</DOCNO>
	<brief_summary>The purpose Phase I/II study establish maximum tolerate dose ( MTD ) and/or recommend phase 2 dose ( RP2D ) evaluate safety , antitumor activity pharmacokinetic ( PK ) profile MAK683 patient advanced malignancy Diffuse Large B cell Lymphoma ( DLBCL ) , nasopharyngeal carcinoma ( NPC ) advance solid tumor effective standard treatment available .</brief_summary>
	<brief_title>Safety Efficacy MAK683 Adult Patients With Advanced Malignancies</brief_title>
	<detailed_description>The purpose phase I trial characterize safety tolerability determine maximum tolerate dose ( MTD ) and/or recommend phase 2 dose ( RP2D ) MAK683 . The purpose phase II trial evaluate anti-tumor activity MAK683 .</detailed_description>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Eastern Cooperative Oncology Group ( ECOG ) : 0 2 2 . Relapsed refractory diffuse large B cell lymphoma , follicular lymphoma , B cell lymphoma measurable disease determine NonHodgkin 's Lymphoma Cheson response criterion ( 2014 ) 3 . Advanced recurrent/metastatic solid tumor , include nasopharyngeal carcinoma ( Phase II part Nasopharyngeal carcinoma patient without homozygous p16deletion ) , prostate cancer ( castration resistant ) , gastric cancer , ovarian cancer indication support emerge data , measurable disease determine RECIST 1.1 . 1 . Other malignant disease one treat study 2 . Severe and/or uncontrolled medical condition investigator 's opinion could affect safety individual impair assessment study result . 3 . Bcell lymphoma patient receive prior allogeneic stem cell transplant 4 . Patient receive anticancer therapy within defined time frame prior first dose study treatment 5 . Symptomatic central nervous system ( CNS ) involvement neurologically unstable require increase dos steroid control . 6 . Patient range laboratory value define : 1 ) Insufficient bone marrow function screening : Platelets ≤ 50,000/mm3 Hemoglobin ( Hgb ) ≤ 80 g/L Absolute neutrophil count ( ANC ) ≤ 1000/mm3 2 ) Insufficient hepatic renal function screening : ALP , ALT , AST &gt; 3 x ULN ( &gt; 5 x ULN subject liver metastasis ) Total bilirubin &gt; 1.5 x ULN Serum creatinine &gt; 1.5 x ULN and/or creatinine clearance ≤ 50 mL/min 7.Unable stop prohibit medication , include strong cytochrome CYP3A4 inhibitor inducer , long act proton pump inhibitor drug know risk cause TdP 8.Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MAK683 , advanced malignancy , DLBCL , EED - Embryonic ectoderm development , EZH2 - Enhancer zeste homolog 2</keyword>
</DOC>